Screener
R&D at other companies
Other financials
Where this comes from
Reported directly by Syndax Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 4:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-197154
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Total revenues | 64,864 | 20,042 |
| Operating expenses: | ||
| Cost of product sales | $2,633 | $885 |
| Research and development | 58,845 | 61,636 |
| Selling, general and administrative | 37,588 | 41,031 |
| Collaboration loss | — | 247 |
| Total operating expenses | 99,066 | 103,799 |
| Loss from operations | (34,202) | (83,757) |
Item 1: Financial Statements
FAQ
- What is Syndax Pharmaceuticals's R&D?
- Syndax Pharmaceuticals (SNDX) reported R&D of $58.85M in Q1 2026.
- How has Syndax Pharmaceuticals's R&D changed year-over-year?
- Syndax Pharmaceuticals's R&D decreased by 4.5% year-over-year, from $61.64M to $58.85M.
- What is the long-term trend for Syndax Pharmaceuticals's R&D?
- Over 4 years (2021 to 2025), Syndax Pharmaceuticals's R&D has grown at a 30.9% compound annual growth rate (CAGR), from $88.25M to $258.78M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Syndax Pharmaceuticals's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude